Selegiline Transdermal System in the Prevention of Relapse of Major Depressive Disorder: A 52-Week, Double-blind, Placebo-Substitution, Parallel-Group Clinical Trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The selegiline transdermal system (STS) is a monoamine oxidase inhibitor (MAOI) with unique pharmacokinetic and pharmacodynamic properties that was developed to overcome limitations of orally administered MAOIs, particularly dietary tyramine restrictions. We present data from a long-term study assessing the safety and efficacy of initial and continuation STS therapy in patients with major depressive disorder (MDD). After 10 weeks of treatment with STS 6 mg/24 h, 322 patients who responded with a 17-item Hamilton Depression Rating Scale score of 10 or less were randomly assigned to double-blind treatment with STS 6 mg/24 h or placebo for 52 weeks. Relapse was defined as meeting the following criteria on 2 consecutive visits: (1) 17-item Hamilton Depression Rating Scale score of 14 or more, (2) a Clinical Global Impression of Severity score of 3 or more with a 2-point increase from double-blind baseline, and (3) the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a major depressive episode. At study week 52, significantly fewer STS patients experienced relapse of major depressive episode (25/149 [16.8%]) compared with placebo (50/163 [30.7%]) (P = 0.0025). In addition, patients receiving STS experienced a significantly longer time to relapse compared with those receiving placebo (P = 0.0048). The safety profile of STS was similar to placebo, with the exception of application-site reactions (STS, 15.2%; placebo, 3.7%). No cases of hypertensive crisis were reported, despite the lack of requirement for dietary tyramine restrictions. In conclusion, STS was well tolerated and efficacious in maintaining a sustained response in MDD patients. The results of this study suggest that STS may be suitable in the long-term treatment of MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2×
“Similar to other relapse prevention trials, most relapses and premature discontinuations occurred within the first several months after placebo substitution.(29,30) As a result, this may have limited the applicability of our findings to the optimal length of continuation therapy with the STS.”
ResultTranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.2.195 · Cited by 167
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94 · cited 1×
“Furthermore, the relapse rates and relative difference in relapse rates between treatment groups in the current study are comparable with those recently reported for duloxetine and escitalopram (17% for duloxetine and 29% for placebo [a difference of 12%] and 26% for escitalopram and 40% for placebo [a difference of 1…”
ResultSafety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain
Nemeroff, C. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0506 · Cited by 86
Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.004 · Cited by 69 · cited 1×
“High rates of treatment discontinuation (eg, >50%) are commonly reported during long-term antidepressant studies.(46,47) In the present study, unfortunately, the most common reasons for premature discontinuation were ‘‘lost to follow-up’’ and ‘‘withdrawal of consent’’ rather than more informative reasons such as adver…”
BackgroundTerra, J. L., & Montgomery, S. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00001 · Cited by 51
Cited by
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“…et al., 2002 Paroxetine-IR 428 0.38 (0.21–0.70) >100 1.27 Weihs et al., 2002 Bupropion 828 1.41 (1.20–1.64) 6.7 (4.6–12) 2.64 Fava et al., 2005 Hypericum 88 1.28 (0.81–2.03) 9.0 (3.1 to >100) 1.66 Fava et al., 2005 Fluoxetine 90 1.05 (0.69–1.58) 45 (4.4 to >100) 1.81 Amsterdam and Bodkin…”
InfluentialAndrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
Metadata
- Authors
- Amsterdam, J. D., & Bodkin, J. A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2006-12
- Volume
- 26
- Issue
- 6
- Pages
- 579-586
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2054339311
- Cited by
- 72
- References
- 8
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selegiline Transdermal System in the Prevention of Relapse of Major Depressive Disorder: A 52-Week, Double-blind, Placebo-Substitution, Parallel-Group Clinical Trial. https://app.cochat.ai/papers/10.1097/01.jcp.0000239794.37073.70
- The paper
- Amsterdam, J. D., & Bodkin, J. A. (2006). Selegiline Transdermal System in the Prevention of Relapse of Major Depressive Disorder: A 52-Week, Double-blind, Placebo-Substitution, Parallel-Group Clinical Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000239794.37073.70
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.